Holen Sie sich die Stockscreener-App
75.82
7.42%
-6.08
Vorhandelsmarkt:
75.81
-0.010
-0.01%
Schlusskurs vom Vortag:
$81.90
Offen:
$81
24-Stunden-Volumen:
1.42M
Relative Volume:
1.83
Marktkapitalisierung:
$5.18B
Einnahmen:
$189.76M
Nettoeinkommen (Verlust:
$-196.54M
KGV:
-24.39
EPS:
-3.1087
Netto-Cashflow:
$-156.63M
1W Leistung:
-13.30%
1M Leistung:
-18.24%
6M Leistung:
-23.54%
1J Leistung:
+41.75%
1-Tages-Spanne:
$75.44
$83.65
1-Wochen-Bereich:
$75.44
$91.12
52-Wochen-Spanne:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
75.82 | 5.18B | 189.76M | -196.54M | -156.63M | -3.1087 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-11-25 | Eingeleitet | Citigroup | Buy |
| 2025-11-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
-7.42% for Rhythm Pharmaceuticals stock as sellers dominate near key support - Traders Union
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - msn.com
Vanguard disaggregates holdings; reports 0 shares in Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharma down as FDA extends review period for Imcivree label expansion - msn.com
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Rhythm Pharmaceuticals Gains EMA Backing for IMCIVREE Expansion - TipRanks
[8-K] RHYTHM PHARMACEUTICALS, INC. Reports M... - Stock Titan
Leerink reiterates Rhythm Pharmaceuticals stock rating on CHMP opinion By Investing.com - Investing.com Canada
Short Squeeze: What is the earnings history of Rhythm Pharmaceuticals IncWeekly Trend Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for - GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment - Yahoo Finance
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic ObesitySlideshow (NASDAQ:RYTM) 2026-03-24 - Seeking Alpha
TD Cowen reiterates Buy on Rhythm Pharmaceuticals stock at $130 - investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RYTM: HC Wainwright & Co. Maintains 'Buy' Rating, Raises Price T - GuruFocus
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on FDA approval - Investing.com Canada
Levels Update: What hedge funds are buying Rhythm Pharmaceuticals IncMarket Rally & Accurate Entry/Exit Alerts - baoquankhu1.vn
Rhythm wins US nod for Imcivree in rare hypothalamic obesity - The Pharma Letter
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $105 - moomoo.com
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - BioSpace
Tech Rally: Is Rhythm Pharmaceuticals Inc. gaining market share2026 PreEarnings & Technical Pattern Based Signals - baoquankhu1.vn
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setme - The National Law Review
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity - Yahoo Finance
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch - marketbeat.com
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide - MarketBeat
Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' - Investor's Business Daily
Rhythm Pharmaceuticals (RYTM) Receives Buy Rating and Raised Pri - GuruFocus
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Ex - GuruFocus
RYTM: Citigroup Raises Price Target on Rhythm Pharmaceuticals | - GuruFocus
Rare obesity treatment for hypothalamic injury patients gets one U.S. pharmacy - Stock Titan
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide - Insider Monkey
RYTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap UpHere's What Happened - MarketBeat
FDA Approves IMCIVREE (Setmelanotide) as First Therapy for Acquired Hypothalamic Obesity in Adults and Children 4+ - Minichart
**Rhythm Pharmaceuticals Surges with Significant Market Moves After FDA Expansion** - stockstotrade.com
Rhythm's therapy becomes first FDA-approved treatment for brain damage-related obesity - Reuters
Rhythm Pharmaceuticals jumps as investors focus on FDA decision timing for hypothalamic obesity label expansion - Quiver Quantitative
Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA - TipRanks
Rhythm Wins FDA Nod for Hypothalamic Obesity Therapy - TipRanks
Why Is Rhythm Pharma Stock Gaining Friday?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% placebo‑adjusted BMI - TradingView
Palatin's Case Strengthens as Rhythm's FDA Approval Validates Hypothalamic Obesity Market (PTN) - Benzinga
Rhythm Pharmaceuticals (Nasdaq: RYTM) gains FDA OK for IMCIVREE in acquired hypothalamic obesity - Stock Titan
Rhythm obesity drug wins broader use from FDA - BioPharma Dive
HC Wainwright Analysts Lower Earnings Estimates for RYTM - MarketBeat
After setback, Rhythm gets good news on Imcivree from FDA - pharmaphorum
Rhythm Pharmaceuticals (RYTM) Gains on FDA Approval for Expanded Use of Imcivree - GuruFocus
Rhythm Pharmaceuticals stock jumps on FDA approval - Investing.com
Rhythm Pharmaceuticals stock jumps on FDA approval By Investing.com - Investing.com Canada
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.03%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):